New MSF report shows unacceptable global double standard in diabetes care, even though better treatments cost little to produce and could be much more affordable
Ahead of the Symposium on Diabetes in Humanitarian Crises, MSF called on pharmaceutical corporations to bring down prices of insulin pens and newer diabetes drugs, so that everyone, everywhere can access optimal care Athens/Geneva, 8